Dr. Kelsey Elizabeth Hirotsu, MD

Dr. Hirotsu practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Hirotsu's NPI, 1780115741, was assigned on March 22, 2017. Dr. Hirotsu graduated from Stanford University School Of Medicine in 2017. Dr. Hirotsu holds California license A156863.

Dr. Hirotsu's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Hirotsu's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Hirotsu to 1 more hospital and 1 medical group, each named with a free account. Dr. Hirotsu's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hirotsu practices, 2 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Hirotsu's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Hirotsu is board certified in dermatology by the American Board of Dermatology. Dr. Hirotsu is licensed in California.

Dmand AI lists benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, skin cyst and skin discoloration among the conditions Dr. Hirotsu treats.

CMS data shows 2,175 Medicare services from Dr. Hirotsu across 32 procedure codes in 2024, for 498 Medicare patients. Medicare paid $352,240 for them. Every service was in an office.

CMS counts 498 Medicare patients who saw Dr. Hirotsu in 2024. The largest group is 65 to 74, with 220 patients. 71% of them have high cholesterol, and 66% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Hirotsu's median patient age at 66, with 44% women.

In 2024, Dr. Hirotsu wrote 350 Medicare Part D claims for 211 patients. 98% of them were for generic drugs. CMS names the drug for 265 of them, across 6 drugs with 11 or more claims each, at $2,164 in total drug cost. In 2023, CMS named 141 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Hirotsu for performance year 2024, reported as part of a group. Dr. Hirotsu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hirotsu as offering telehealth. CMS counts 154 procedures of melanoma (skin cancer) excision by Dr. Hirotsu, more than 96% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 24 papers to Dr. Hirotsu, published from 2017 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Skin Neoplasms, Mohs Surgery and Skin. Dr. Hirotsu has published most often in J Am Acad Dermatol. Dr. Hirotsu's most frequent co-authors are Bernice Yu Jing Kwong, MD, Sumaira Zareen Aasi, MD and Nour Kibbi, MD.

CMS Open Payments shows 1 general payment to Dr. Hirotsu from 1 drug or device company in 2021. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $46.

Dr. Hirotsu graduated from Stanford University School Of Medicine in 2017.

Dr. Hirotsu is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.